| (19) |
 |
|
(11) |
EP 3 241 840 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
07.02.2018 Bulletin 2018/06 |
| (43) |
Date of publication A2: |
|
08.11.2017 Bulletin 2017/45 |
| (22) |
Date of filing: 21.01.2011 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
| (30) |
Priority: |
22.01.2010 US 336478 P
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
11735264.1 / 2525824 |
| (71) |
Applicant: The Board of Trustees of the Leland Stanford
Junior University |
|
Stanford, CA 94305-2038 (US) |
|
| (72) |
Inventors: |
|
- GIACCIA, Amato J.
Palo Alto, CA 94301 (US)
- RANKIN, Erinn Bruno
Redwood City, CA 94065 (US)
- COCHRAN, Jennifer R.
Stanford, CA 94305 (US)
- JONES, Douglas
Newton, MA 02548 (US)
- KARIOLIS, Mihalis
San Mateo, CA 94401 (US)
- FUH, Katherine
Palo Alto, CA 94306 (US)
- MIAO, Yu
Sunnyvale, CA 94087 (US)
|
| (74) |
Representative: Harrison, Susan Joan et al |
|
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE
City Tower
40 Basinghall Street
London EC2V 5DE (GB) |
|
| |
|
| (54) |
INHIBITION OF AXL SIGNALING IN ANTI-METASTATIC THERAPY |
(57) Compositions and methods are provided for alleviating cancer in a mammal by administering
a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein
activity, for example by competitive or non-competitive inhibition of the binding
interaction between AXL and its ligand GAS6.